期刊文献+

结直肠癌患者转录因子PRR13的表达与肿瘤临床和病理特征及预后的相关性研究 被引量:6

Correlation between the expression of transcription factor PPR13 and the clinical and pathological characteristics and prognosis in colorectal cancer patients
下载PDF
导出
摘要 目的研究PRR13基因在结直肠癌组织和正常组织中的表达特点,分析不同染色程度所代表的意义与结直肠癌临床及病理特征之间的联系,以及该基因与结直肠癌患者生存预后的可能相关性。方法采用回顾性研究方法,收集2012年1月至2013年12月于首都医科大学附属北京友谊医院经病理确诊的161例结直肠癌患者的手术肿瘤标本和包含肿瘤部位、浸润深度、分化类型、pTNM分期、淋巴转移、和远处转移及生存预后等信息的临床资料。采用免疫组织化学法检测正常结直肠黏膜、结直肠癌病灶中PRR13蛋白的表达,分析结直肠癌组织中PRR13蛋白表达与临床病理因素的关系,采用Kaplan-Meier生存曲线分析结直肠癌组织中PRR13蛋白表达与患者预后的关系,采用Cox单因素回归和多因素回归分析结直肠癌预后的影响因素。结果在结直肠正常组织中PRR13蛋白大部分在细胞核中表达(142/145,97.9%),仅少部分正常组织标本细胞质中存在该蛋白(27/145,18.6%);在癌组织中,PRR13蛋白在细胞核中的表达明显降低(30/145,20.7%),大部分是无表达(131/145,79.3%),而在细胞质的表达较正常组织的表达明显升高(61/145,42.1%)。PRR13基因表达的高低,与肿瘤的分化类型、pTNM分期、淋巴转移、远处转移有显著的统计学相关性(P<0.05);而与患者性别、年龄、肿瘤部位、黏液结构、浸润深度等因素无相关性(P>0.05)。此外,PRR13高表达的患者较低表达的患者,其5年生存率显著下降,差异具有统计学意义(P<0.01)。结论结直肠癌中PRR13基因表达的强弱,可在一定程度上反映其相应的临床及病理特征,并且PRR13的表达可作为判断结直肠癌患者预后的指标之一。 Objective To study the expression characteristics of PRR13 gene in colorectal cancer(CRC)tissues and normal tissues,analyze the association between different staining degrees and clinical and pathological characteristics,and also the possible correlation between PRR13 gene and survival prognosis of CRC patients.Methods The tumor specimens and clinical data such as tumor location,invasion depth,differentiation,pTNM stage,lymphatic metastasis,distant metastasis,and survival prognosis of 161 patients diagnosed with CRC in Beijing Friendship Hospital,Capital Medical University from January 2012 to December 2013 were retrospectively collected.The expression of PRR13 protein in normal colorectal mucosa and colorectal carcinoma tissue were detected by immunohistochemistry.The relationship between PRR13 protein expression in colorectal cancer tissues and clinical pathological factors was analyzed.Kaplan-Meier survival curve was used to make the survival analysis and Cox univariate regression and multivariate regression were used to analyze the prognostic factors of the colorectal carcinoma.Results In normal colorectal tissues,the protein was mostly expressed in the nucleus(142/145,97.9%),and only a few normal tissues had the protein in the cytoplasm(27/145,18.6%).In carcinoma tissues,the expression of PRR13 protein in the nucleus was significantly decreased(30/145,20.7%).Most of the PRR13 protein was not expressed(131/145,79.3%),while the expression in cytoplasm was significantly higher than that in normal tissues(61/145,42.1%).There were statistically significant correlations between PRR13 gene expression and tumor differentiation,pTNM stage,lymphatic metastasis and distant metastasis(P<0.05).There was no statistically significant correlation with gender,age,tumor site,mucous structure and invasion depth(P>0.05).The 5-year overall survival rate of patients with high expression of PRR13 was significantly lower than those with low expression,the difference was statistically significant(P<0.01).Conclusion The expression of PRR13 gene can reflect the clinical and pathological features of CRC to a certain extent,and PRR13 can be used as one of the prognostic indicators for CRC patients.
作者 杨鋆 林华骏 柴睿智 赵宝一 李东明 张伟涛 金岚 杨盈赤 张忠涛 YANG Yun;LIN Hua-jun;CHAI Rui-zhi(Department of General Surgery,Beijing Friendship Hospital,Capital Medical University,Beijing Key Laboratory of Cancer Invasion and Metastasis Research&National Clinical Research Center for Digestive Diseases,Beijing 100050,China.)
出处 《临床和实验医学杂志》 2020年第16期1687-1692,共6页 Journal of Clinical and Experimental Medicine
基金 首都医科大学结直肠肿瘤临床诊疗与研究中心(编号:1192070313) 国家科技支撑计划课题(编号:2015BAI13B09) 国家重点研发计划资助(编号:2017YFC0110904)。
关键词 结直肠癌 PRR13基因 临床特征 病理特征 预后 Colorectal cancer PRR13 gene Clinical features Pathological features Prognosis
  • 相关文献

参考文献4

二级参考文献19

  • 1Lih CJ,Wei W,Cohen SN.Txrl:a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes[J].Genes Dev,2006,20(15):2082-2095.
  • 2Rowinsky EK,Donehower RC.Paclitaxel (taxol)[J].N Eng1 J Med,1995,332(15):1004-1014.
  • 3Sparano JA,Wang M,Martino S,et al.Weekly paclitaxel in the adjuvant treatment of breast cancer[J].N Engl J Med,2008,358(16):1663-1671.
  • 4Hutchinson E,A taxing problem[J].Nat Rev Cancer,2006,6(8):578-579.
  • 5Ferguson T,Wilcken N,Vagg R,et al.Taxanes for adjuvant treatmerit of early breast cancer[J].Cochrane Database Syst Rev,2007,(4):CD004421.
  • 6Bedard PL,Di Leo A,Piccart-Gebhart MJ.Taxanes:optimizing adjuvant chemotherapy for early-stage breast cancer[l].Nat Rev Glin Oncol,2010,7(1):22-36.
  • 7Kutuk O,Letai A.Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxd resistance and can be reversed by ABT-737[J].Cancer Res,2008,68(19):7985-7994.
  • 8Papadaki C,Mavroudis D,Trypaki M,et al.Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen[J].Clin Cancer Res,2009,15(11):3827-3833.
  • 9Marsh S,McLeod HL.Pharmacogenetics and oncology treatment for breast cancer.Expert Opin Pharmacother,2007,8(2):119-127.
  • 10Moore A.Breast-cancer therapy--looking back to the future.New Engl J Med,2007,357(15):1547-1549.

共引文献10

同被引文献57

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部